[go: up one dir, main page]

AR113224A1 - Conjugados de anticuerpo que comprenden un agonista de sting - Google Patents

Conjugados de anticuerpo que comprenden un agonista de sting

Info

Publication number
AR113224A1
AR113224A1 ARP180101063A ARP180101063A AR113224A1 AR 113224 A1 AR113224 A1 AR 113224A1 AR P180101063 A ARP180101063 A AR P180101063A AR P180101063 A ARP180101063 A AR P180101063A AR 113224 A1 AR113224 A1 AR 113224A1
Authority
AR
Argentina
Prior art keywords
antibody conjugates
sting agonist
conjugates including
immunoconjugates
methods
Prior art date
Application number
ARP180101063A
Other languages
English (en)
Inventor
Yongqin Wan
Tom Yao Wu
- Uno Tetsuo Hsiang
George Scott Tria
Leonard Sung
Weijia Ou
Chudiobioma Ndubaku
Sarah Mwhirter
Jeffrey Mkenna
Justin Leong
Thanh Ngoc Lan Le
George Edwin Katibah
Shailaja Kasibhatla
David Kanne
Xueshi Hao
Laura Glickman
Kelsey Gauthier
Thomas W Dubensky
Charles Y Cho
Stephen Canham
Jacob Robert Bruml
Original Assignee
Novartis Ag
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Aduro Biotech Inc filed Critical Novartis Ag
Publication of AR113224A1 publication Critical patent/AR113224A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente inmunoconjugados que comprenden agonistas de STING. También se dan a conocer métodos para producir los inmunoconjugados y métodos de tratamiento del cáncer usando los inmunoconjugados.
ARP180101063A 2017-04-28 2018-04-25 Conjugados de anticuerpo que comprenden un agonista de sting AR113224A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762491879P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
AR113224A1 true AR113224A1 (es) 2020-02-19

Family

ID=62165655

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101063A AR113224A1 (es) 2017-04-28 2018-04-25 Conjugados de anticuerpo que comprenden un agonista de sting

Country Status (5)

Country Link
EP (1) EP3615080A1 (es)
JP (1) JP2020517700A (es)
CN (1) CN110799218A (es)
AR (1) AR113224A1 (es)
WO (1) WO2018200812A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102847350B1 (ko) 2015-11-25 2025-08-19 주식회사 리가켐바이오사이언스 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
JP7664680B2 (ja) 2017-03-29 2025-04-18 リガケム バイオサイエンシズ， インク． ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
TW201922263A (zh) 2017-11-10 2019-06-16 日商武田藥品工業股份有限公司 干擾素基因刺激蛋白之調節化合物，及製造和使用方法
EP3505188A1 (en) * 2017-12-29 2019-07-03 Invivogen Pro-cyclic dinucleotide conjugates for cytokine induction
SG11202010443WA (en) 2018-05-09 2020-11-27 Legochem Biosciences Inc Compositions and methods related to anti-cd19 antibody drug conjugates
CN112512531B (zh) * 2018-06-01 2024-04-09 卫材R&D管理有限公司 用于膀胱癌的治疗的方法
CA3106110A1 (en) 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2020089815A1 (en) * 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
CN113348181A (zh) * 2018-10-31 2021-09-03 诺华股份有限公司 包含sting激动剂的dc-sign抗体缀合物
EP4406555A3 (en) * 2018-12-21 2024-11-06 Novartis AG Antibodies to pmel17 and conjugates thereof
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP7621974B2 (ja) 2019-05-09 2025-01-27 アリゴス セラピューティクス インコーポレイテッド Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物
CN119770674A (zh) 2019-05-10 2025-04-08 武田药品工业株式会社 抗体药物缀合物
US20230081720A1 (en) 2019-05-20 2023-03-16 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP3980423A1 (en) 2019-06-10 2022-04-13 Sutro Biopharma, Inc. 5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
WO2020248065A1 (en) * 2019-06-12 2020-12-17 Ontario Institute For Cancer Research (Oicr) Unsaturated heterocycloalkyl and heteroaromatic acyl hydrazone linkers, methods and uses thereof
CN117838878A (zh) 2019-07-19 2024-04-09 免疫传感器治疗股份有限公司 抗体-sting激动剂缀合物及其在免疫疗法中的用途
JP2022543086A (ja) 2019-08-02 2022-10-07 メルサナ セラピューティクス インコーポレイテッド がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物
JP7414965B2 (ja) * 2019-08-21 2024-01-16 ザ スクリプス リサーチ インスティテュート インターフェロン遺伝子の刺激因子ｓｔｉｎｇの二環式アゴニスト
KR20210028544A (ko) * 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
WO2021046426A1 (en) * 2019-09-06 2021-03-11 Sperovie Biosciences, Inc. Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies
US20230074385A1 (en) * 2019-12-23 2023-03-09 Eisai R&D Management Co., Ltd. Method for producing eribulin-based antibody-drug conjugate
CA3168368A1 (en) * 2020-03-06 2021-09-10 Masayuki Ishizaki Antibody-drug conjugate including novel cyclic dinucleotide derivative
US20230338564A1 (en) * 2020-03-31 2023-10-26 Orum Therapeutics, Inc. Neodegrader conjugates
CN116196435B (zh) * 2020-04-02 2025-12-02 梅尔莎纳医疗公司 包含sting激动剂的抗体药物缀合物
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
WO2021216572A1 (en) 2020-04-20 2021-10-28 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
CN111592570B (zh) * 2020-05-15 2022-04-29 清华大学 新型sting激动剂及其制备方法和应用
IL298148A (en) 2020-05-15 2023-01-01 Immunesensor Therapeutics Inc Sting agonist combination therapies with immune checkpoint inhibitors
IL302390A (en) * 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
AU2022253902A1 (en) 2021-04-10 2023-11-02 Genmab A/S Folr1 binding agents, conjugates thereof and methods of using the same
JP2024514707A (ja) 2021-04-20 2024-04-02 アンスティテュ・クリー 免疫療法における使用のための組成物及び方法
JP7742892B2 (ja) 2021-04-23 2025-09-22 ジェンマブ エー／エス 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
CN118284423A (zh) 2021-07-23 2024-07-02 免疫传感器治疗股份有限公司 Sting激动剂与细胞因子的组合治疗
TW202342105A (zh) * 2021-12-17 2023-11-01 大陸商北京加科思新藥研發有限公司 包含可用作sting激動劑的化合物的化合物-連接基構建體及其用途
CN115060902B (zh) * 2022-05-13 2025-07-11 上海市第十人民医院 可作为肿瘤诊断和预后分析标志物的cGAS甲基化修饰及其检测试剂和应用
EP4558511A2 (en) 2022-07-21 2025-05-28 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024100452A2 (en) * 2022-11-08 2024-05-16 Legochem Biosciences, Inc. Heterocyclic compounds as sting agonists
KR20250129814A (ko) * 2023-01-18 2025-08-29 타이리간드 바이오사이언스 (상하이) 리미티드 항체-약물 접합체 및 이의 용도
KR20250160354A (ko) 2023-03-10 2025-11-12 노파르티스 아게 Panras 억제제 항체-약물 콘쥬게이트 및 이의 사용 방법
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
WO2025140587A1 (zh) * 2023-12-27 2025-07-03 上海迪诺医药科技有限公司 环状二核苷酸化合物、其偶联物及应用
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025233676A1 (en) * 2024-05-08 2025-11-13 Ligachem Biosciences Inc. Compositions and methods related to a combination therapy of sting agonists and immune checkpoint inhibitors
WO2025233679A1 (en) * 2024-05-08 2025-11-13 Ligachem Biosciences Inc. Compositions and methods related to a combination therapy of sting agonists and antibody drug conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69839147T2 (de) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. Künstliche antikörperpolypeptide
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN104524590B (zh) 2008-04-30 2019-06-21 伊缪诺金公司 交联剂和它们的用途
IN2015DN02913A (es) 2012-11-30 2015-09-18 Novartis Ag
KR20150095668A (ko) 2012-12-13 2015-08-21 아두로 바이오테크, 인코포레이티드 규정된 입체화학을 갖는 환식 퓨린 다이뉴클레오타이드를 포함하는 조성물, 그리고 이의 제조 방법 및 용도
MX2015010146A (es) * 2013-02-08 2016-05-31 Novartis Ag Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
US9724408B2 (en) 2013-05-18 2017-08-08 Aduro Biotech, Inc. Compositions and methods for activating stimulator of interferon gene-dependent signalling
CA2931146C (en) 2013-11-22 2022-06-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
MX2016015928A (es) 2014-06-04 2017-03-20 Glaxosmithkline Ip Dev Ltd Dinucleotidos ciclicos como moduladores de sting.
WO2016096174A1 (en) 2014-12-16 2016-06-23 Invivogen Fluorinated cyclic dinucleotides for cytokine induction
JP6692826B2 (ja) * 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
WO2016161372A1 (en) * 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
HK1252343A1 (zh) 2015-07-02 2019-05-24 春季银行制药股份有限公司 用於治疗病毒感染的组合物和方法
TW201717968A (zh) 2015-07-14 2017-06-01 春季銀行製藥公司 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物
WO2017019896A1 (en) * 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
UA123701C2 (uk) 2015-08-13 2021-05-19 Мерк Шарп І Доум Корп. Циклічні динуклеотидні сполуки як агоністи sting
WO2017100305A2 (en) * 2015-12-07 2017-06-15 Opi Vi - Ip Holdco Llc Composition of antibody construct-agonist conjugates and methods of use thereof
CN106540256A (zh) * 2016-03-27 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
TW201803886A (zh) 2016-07-06 2018-02-01 史貝羅威生物科學有限公司 化合物、組合物及用於治療疾病之方法
WO2018009648A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2018013887A1 (en) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
EP3484504A4 (en) 2016-07-15 2020-07-29 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE

Also Published As

Publication number Publication date
WO2018200812A1 (en) 2018-11-01
JP2020517700A (ja) 2020-06-18
EP3615080A1 (en) 2020-03-04
CN110799218A (zh) 2020-02-14

Similar Documents

Publication Publication Date Title
AR113224A1 (es) Conjugados de anticuerpo que comprenden un agonista de sting
MX2021007620A (es) Inmunoconjugados de anticuerpos receptor huerfano similar al receptor tirosina cinasa 1 (ror1).
ECSP18038868A (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CL2019003050A1 (es) Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinación.
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
UY38433A (es) Conjugados de anticuerpo dc–sign que comprenden agonistas de sting
CY1124230T1 (el) Αγωνιστης υποδοχεα γλυκοκορτικοειδων και ανοσοσυζευγματα αυτου
CL2018003406A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
MX2024006675A (es) Anticuerpos monoclonales del receptor del factor de crecimiento 1 tipo insulina (igf-1r) y usos de los mismos.
CO2018004152A2 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
CO2017010618A2 (es) Anticuerpos contra icos
MX2017003126A (es) Anticuerpos anti-her2 e inmunoconjugados.
CO2018005433A2 (es) Conjugados de fármaco de anticuerpo her2 específicos de sitio
CL2025000404A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
MX2017003022A (es) Anticuerpos anti-cll-1 e inmunoconjugados.
CL2019003168A1 (es) Mejoras farmacocinéticas de quelatos bifuncionales y usos de los mismos.
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
MX2020007748A (es) Metodos para tratar canceres con anticuerpos anti-pd-1 antagonistas.
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
MX2019004690A (es) Constructos de anticuerpos.
MX2015015091A (es) Terapia de combinacion de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-farmaco.
MX370829B (es) Uso de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd22-fármaco.

Legal Events

Date Code Title Description
FB Suspension of granting procedure